title: A gene expression and systems pathway analysis of the effects of clozapine compared to haloperidol in the mouse brain implicates susceptibility genes for schizophrenia.
abstract: Clozapine has markedly superior clinical properties compared to other antipsychotic drugs but the side effects of agranulocytosis, weight gain and diabetes limit its use. The reason why clozapine is more effective is not well understood. We studied messenger RNA (mRNA) gene expression in the mouse brain to identify pathways changed by clozapine compared to those changed by haloperidol so that we could identify which changes were specific to clozapine. Data interpretation was performed using an over-representation analysis (ORA) of gene ontology (GO), pathways and gene-by-gene differences. Clozapine significantly changed gene expression in pathways related to neuronal growth and differentiation to a greater extent than haloperidol; including the microtubule-associated protein kinase (MAPK) signalling and GO terms related to axonogenesis and neuroblast proliferation. Several genes implicated genetically or functionally in schizophrenia such as frizzled homolog 3 (FZD3), U2AF homology motif kinase 1 (UHMK1), pericentriolar material 1 (PCM1) and brain-derived neurotrophic factor (BDNF) were changed by clozapine but not by haloperidol. Furthermore, when compared to untreated controls clozapine specifically regulated transcripts related to the glutamate system, microtubule function, presynaptic proteins and pathways associated with synaptic transmission such as clathrin cage assembly. Compared to untreated controls haloperidol modulated expression of neurotoxic and apoptotic responses such as NF-kappa B and caspase pathways, whilst clozapine did not. Pathways involving lipid and carbohydrate metabolism and appetite regulation were also more affected by clozapine than by haloperidol.
authors: Molecular Psychiatry Laboratory, University College London, London, UK.
authors: Mie A
authors: MA
authors: Rizig
authors: Andrew
authors: A
authors: McQuillin
authors: Aylwin
authors: A
authors: Ng
authors: Michelle
authors: M
authors: Robinson
authors: Andrew
authors: A
authors: Harrison
authors: Marketa
authors: M
authors: Zvelebil
authors: Steve P
authors: SP
authors: Hunt
authors: Hugh M
authors: HM
authors: Gurling
mesh_terms: D000818:Animals; D014150:Antipsychotic Agents / Q000097:blood / Q000494:pharmacology*; D001921:Brain / Q000187:drug effects* / Q000378:metabolism; D018797:Cell Cycle Proteins / Q000235:genetics / Q000378:metabolism; D003024:Clozapine / Q000097:blood / Q000494:pharmacology*; D004195:Disease Models, Animal; D020869:Gene Expression Profiling; D005786:Gene Expression Regulation / Q000187:drug effects*; D006220:Haloperidol / Q000097:blood / Q000494:pharmacology*; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D008868:Microtubule Proteins / Q000235:genetics / Q000378:metabolism; D009419:Nerve Tissue Proteins / Q000235:genetics / Q000378:metabolism; D009474:Neurons / Q000187:drug effects* / Q000378:metabolism; D020411:Oligonucleotide Array Sequence Analysis; D009928:Organ Specificity; D010865:Pilot Projects; D012333:RNA, Messenger / Q000378:metabolism; D012559:Schizophrenia / Q000188:drug therapy / Q000378:metabolism*
chemical_list: D014150:Antipsychotic Agents; D018797:Cell Cycle Proteins; D008868:Microtubule Proteins; D009419:Nerve Tissue Proteins; D012333:RNA, Messenger; D003024:Clozapine; D006220:Haloperidol